BridgeMD
Treatments of COVID-19 in primary care in the Netherlands
EU CTIS ID: 2022-501559-99-00
What this study is testing
To assess the effectiveness of treatments provided on time to recovery amongst patients with COVID-19 in the community who are at higher risk of a complicated course of disease.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participant is willing and able to give informed consent for participation in the study.
- Participant is willing and able to comply with all trial procedures.
- Participant has an e-mail address, mobile phone and a laptop/computer/tablet that allows video calling.
- A positive test for COVID-19 (can be either RT-PCR, LAMP, antigen or self-test), which was taken fewer than 8 days ago (7 days or less).
- The participant experiences symptoms of COVID-19. These symptoms may include, but are not limited to, shortness of breath, general feeling of being unwell, muscle pain, sore throat, diarrhoea, vomiting, fever, running nose, sneezing and coughing, and they must have had them for 7 days or less.
- Patients aged ≥18-60 years who are eligible for the annual influenza vaccine.
You likely can't join if
- Currently admitted to hospital
- Almost recovered (generally much improved and symptoms now mild or almost absent)
- Intervention specific (Montelukast): Known hypersensitivity to montelukast
- Intervention specific (Montelukast): Concomitant use of montelukast
- Intervention specific (Montelukast): Using Fenytoine, Fenobarbital, Rifampicine, Carbamazepine or St John’s wort
See the full eligibility criteria
- Participant is willing and able to give informed consent for participation in the study.
- Participant is willing and able to comply with all trial procedures.
- Participant has an e-mail address, mobile phone and a laptop/computer/tablet that allows video calling.
- A positive test for COVID-19 (can be either RT-PCR, LAMP, antigen or self-test), which was taken fewer than 8 days ago (7 days or less).
- The participant experiences symptoms of COVID-19. These symptoms may include, but are not limited to, shortness of breath, general feeling of being unwell, muscle pain, sore throat, diarrhoea, vomiting, fever, running nose, sneezing and coughing, and they must have had them for 7 days or less.
- Patients aged ≥18-60 years who are eligible for the annual influenza vaccine.
- Patients aged ≥60 years
- Currently admitted to hospital
- Almost recovered (generally much improved and symptoms now mild or almost absent)
- Intervention specific (Montelukast): Known hypersensitivity to montelukast
- Intervention specific (Montelukast): Concomitant use of montelukast
- Intervention specific (Montelukast): Using Fenytoine, Fenobarbital, Rifampicine, Carbamazepine or St John’s wort
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.